re: gone Its still above issue price, for a company that will miss prospectus numbers (on NPAT basis) by 20-25%....there's still potential for more downside on that basis alone.
Revised FY05 NPAT is now $9.9M. Market Cap is $143.5M (@ $1.60), that puts it on a FY05 PE Multiple of 14.5 times.
For a no-growth (or at best very smal growth) company, that's probably too high.
I don't hold.
- Forums
- ASX - By Stock
- selling all but gone dry
LIP
lipa pharmaceuticals limited
re: gone Its still above issue price, for a company that will...
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LIP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online